This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Deaths Mar Trial of Celgene Drug

List agrees that MDS patients with a 5q minus deletion are generally lower risk and have a better prognosis than other MDS patients. But that doesn't mean 5q minus patients aren't sick or at risk for death; he cites statistics from medical literature that show these patients, even though they have a low-grade disease, can still have an annual mortality rate as high as 10%.

If List's historical mortality statistics are accurate, then the 7% death rate in the Revlimid study -- again, assuming that analysis is confirmed -- may not be all that unusual. But there are other published medical studies of MDS 5q minus patients that show a longer survival. A study published this year in the medical journal Leukemia by Dr. AAN Giagounidis of St. Johannes Hospital in Germany found median survival of 146 months, or more than 12 years, for this population of MDS patients. That's roughly double the median survival implied by List's 10%-per-year annual mortality statistic.

The best way to measure efficacy and safety of any drug, of course, is to conduct a large, randomized, controlled study in which some patients receive the drug and others receive a placebo. However, that is something Celgene chose not to do with Revlimid in these low-grade MDS patients. If the death rate in the Revlimid study does become a point of concern for regulators, the lack of good control data in which to assess Revlimid's safety might be the factor that forces the FDA to delay approval.

The outlook for Revlimid in low-grade MDS patients is further clouded by the fact that these patients can be treated with blood transfusions or with Vidaza, a drug marketed by Pharmion (PHRM) that was approved earlier this year for all forms of MDS.

Celgene spokesman Gill says it is a mistake to consider 5q minus MDS patients less sick or not in urgent need of new therapies like Revlimid, and he cites a specific example: An MDS patient with the missing 5q gene identified by Celgene required weekly blood transfusions in order to keep his MDS under control. After taking Revlimid for two years, this patient is completely free of the need for transfusions and expects to live a normal, healthy life as long as he continues to take Revlimid, says Gill.

List believes Revlimid is an active drug and approvable by the FDA. "This will be a good package for possible approval, there is nothing excessive here at all."

Celgene has previously stated that it would release data from an analysis of this phase II Revlimid study in 5q minus MDS patients at a corporate event planned in conjunction with the American Society of Hematology annual meeting, which runs Dec. 4-7. But since this particular Revlimid data presentation will not be under the formal auspices of the medical meeting, the breadth and depth of the information Celgene will release is not clear.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. He invites you to send your feedback to
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CELG $118.62 0.82%
AAPL $123.22 -0.82%
FB $83.30 0.35%
GOOG $548.13 -1.30%
TSLA $185.15 -2.80%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs